Literature DB >> 15316718

Effect of fenofibrate on LDL-induced endothelial dysfunction in rats.

Tian-Lun Yang1, Mei-Fang Chen, Bai-Ling Luo, Jing Yu, Jun-Lin Jiang, Yuan-Jian Li.   

Abstract

Previous investigations have demonstrated that asymmetric dimethylarginine (ADMA) is an important factor contributing to endothelial dysfunction, and that fenofibrate has a protective effect on the endothelium in hyperlipidaemic patients. In the present study in rats treated with native low-density lipoprotein (nLDL), we addressed the question of whether the beneficial effect of fenofibrate on endothelial cells is related to reduction of the ADMA concentration. A single injection of nLDL (4 mg/kg, 48 h) markedly reduced endothelium-dependent relaxation in response to acetylcholine and the plasma level of nitrite/nitrate and increased the plasma concentrations of ADMA, malonyldialdehyde (MDA) and tumour necrosis factor-alpha (TNF-alpha). Treatment with fenofibrate (30 or 100 mg/kg) significantly reduced the inhibition of vasodilator responses to acetylcholine, decreased the elevated levels of ADMA, MDA and TNF-alpha, and enhanced the decreased level of nitrite/nitrate in the rats treated with LDL. These results suggest that the protective effect of fenofibrate on endothelial cells in rats treated with LDL may be related to the reduction of ADMA concentration.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15316718     DOI: 10.1007/s00210-004-0971-0

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  23 in total

1.  Impact of vitamin E on plasma asymmetric dimethylarginine (ADMA) in chronic kidney disease (CKD): a pilot study.

Authors:  Rajiv Saran; James E Novak; Anjali Desai; Emil Abdulhayoglu; Jeffrey S Warren; Rami Bustami; Garry J Handelman; Damian Barbato; William Weitzel; Louis G D'Alecy; Sanjay Rajagopalan
Journal:  Nephrol Dial Transplant       Date:  2003-11       Impact factor: 5.992

2.  Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial--FAT).

Authors:  J Malik; V Melenovsky; D Wichterle; T Haas; J Simek; R Ceska; J Hradec
Journal:  Cardiovasc Res       Date:  2001-11       Impact factor: 10.787

3.  LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: involvement of S-adenosylmethionine-dependent methyltransferases.

Authors:  R H Böger; K Sydow; J Borlak; T Thum; H Lenzen; B Schubert; D Tsikas; S M Bode-Böger
Journal:  Circ Res       Date:  2000-07-21       Impact factor: 17.367

4.  Increased inducible nitric oxide synthase expression contributes to myocardial dysfunction and higher mortality after myocardial infarction in mice.

Authors:  Q Feng; X Lu; D L Jones; J Shen; J M Arnold
Journal:  Circulation       Date:  2001-08-07       Impact factor: 29.690

5.  The effect of fenofibrate treatment on endothelium-dependent relaxation induced by oxidative modified low density lipoprotein from hyperlipidemic patients.

Authors:  B Liang; J C McMaster; E A Kroeger; G M Hatch; D Mymin; T Dembinski; G Arthur; G Shen; R Y Man; P C Choy
Journal:  Mol Cell Biochem       Date:  2000-04       Impact factor: 3.396

6.  Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase.

Authors:  A Ito; P S Tsao; S Adimoolam; M Kimoto; T Ogawa; J P Cooke
Journal:  Circulation       Date:  1999-06-22       Impact factor: 29.690

7.  Protective effects of daviditin A against endothelial damage induced by lysophosphatidylcholine.

Authors:  De-Jian Jiang; Jun-Lin Jiang; Gui-Shan Tan; Yan-Hua Du; Kang-Ping Xu; Yuan-Jian Li
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-05-15       Impact factor: 3.000

8.  Effect of high-dose statin treatment on plasma concentrations of endogenous nitric oxide synthase inhibitors.

Authors:  Hannu Päivä; Juha Laakso; Terho Lehtimäki; Marja Isomustajärvi; Inkeri Ruokonen; Reijo Laaksonen
Journal:  J Cardiovasc Pharmacol       Date:  2003-02       Impact factor: 3.105

9.  PPAR alpha activator fenofibrate inhibits myocardial inflammation and fibrosis in angiotensin II-infused rats.

Authors:  Quy N Diep; Karim Benkirane; Farhad Amiri; Jeffrey S Cohn; Dierk Endemann; Ernesto L Schiffrin
Journal:  J Mol Cell Cardiol       Date:  2004-02       Impact factor: 5.000

10.  ADMA and oxidative stress are responsible for endothelial dysfunction in hyperhomocyst(e)inemia: effects of L-arginine and B vitamins.

Authors:  Karsten Sydow; Edzard Schwedhelm; Naoshi Arakawa; Stefanie M Bode-Böger; Dimitrios Tsikas; Burkhard Hornig; Jürgen C Frölich; Rainer H Böger
Journal:  Cardiovasc Res       Date:  2003-01       Impact factor: 10.787

View more
  6 in total

1.  Effect of fenofibrate on the level of asymmetric dimethylarginine in individuals with hypertriglyceridemia.

Authors:  Tian-Lun Yang; Mei-Fang Chen; Xin Xia; Bai-Lin Luo; Yuan-Jian Li
Journal:  Eur J Clin Pharmacol       Date:  2006-01-31       Impact factor: 2.953

2.  Fenofibrate decreases asymmetric dimethylarginine level in cultured endothelial cells by inhibiting NF-kappaB activity.

Authors:  Tian-Lun Yang; Mei-Fang Chen; Bai-Lin Luo; Qi-Ying Xie; Jun-Lin Jiang; Yuan-Jian Li
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-05-25       Impact factor: 3.000

3.  Effects of rosiglitazone on native low-density-lipoprotein-induced respiratory burst in circulating monocytes and on the leukocyte-endothelial interaction in cholesterol-fed rats.

Authors:  Long Sheng Lu; Li Man Hung; Chang Hui Liao; Chau Chung Wu; Ming Jai Su
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-04-21       Impact factor: 3.000

4.  Fenofibrate treatment enhances antioxidant status and attenuates endothelial dysfunction in streptozotocin-induced diabetic rats.

Authors:  Murat Olukman; Ebru Demirel Sezer; Sibel Ulker; Eser Y Sözmen; Gülcihan Mehtap Cınar
Journal:  Exp Diabetes Res       Date:  2010-12-27

5.  Ameliorative effect of combination of benfotiamine and fenofibrate in diabetes-induced vascular endothelial dysfunction and nephropathy in the rat.

Authors:  Pitchai Balakumar; Vishal Arvind Chakkarwar; Manjeet Singh
Journal:  Mol Cell Biochem       Date:  2008-10-02       Impact factor: 3.842

Review 6.  Asymmetric dimethylarginine (ADMA) and endothelial dysfunction: implications for atherogenesis.

Authors:  Maurício Batista Paes Landim; Antônio Casella Filho; Antônio Carlos Palandri Chagas
Journal:  Clinics (Sao Paulo)       Date:  2009-05       Impact factor: 2.365

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.